|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2829303132333435363738...3940» |
- Enrollment closed: D-serine for the Schizophrenia Prodrome (clinicaltrials.gov) - Oct 23, 2012
P2, N=72, Active, not recruiting, Sponsor: Nathan Kline Institute for Psychiatric Research
Recruiting --> Active, not recruiting
- Biomarker, Trial completion: Biomarkers in Schizophrenia (clinicaltrials.gov) - Oct 23, 2012
P2, N=16, Completed, Sponsor: Nathan Kline Institute for Psychiatric Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=4, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed N=200 --> 4
- | New P1/2 trial: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) - Oct 21, 2012
P1/2, N=72, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
- Trial completion: Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=4, Completed, Sponsor: University of North Carolina, Chapel Hill
N=200 --> 4 Active, not recruiting --> Completed
- ziprasidone / Generic mfg.
Enrollment change: Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=24, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Active, not recruiting --> Completed N=36 --> 24
- ziprasidone / Generic mfg.
Trial completion: Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=24, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=36 --> 24 Active, not recruiting --> Completed
- Enrollment open: Feeling of Being in Control of One's Own Action (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=370, Recruiting, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Trial completion, Adverse events: Side Effects of Newer Antipsychotics in Older Adults (clinicaltrials.gov) - Oct 16, 2012
P4, N=406, Completed, Sponsor: Veterans Medical Research Foundation
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Kuvan (sapropterin) / BioMarin, Daiichi Sankyo
New P1/2 trial: Kuvan in People With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Oct 11, 2012
P1/2, N=60, Recruiting, Sponsor: New York State Psychiatric Institute
- Trial completion: Motivational Interviewing to Improve Work Outcomes in Schizophrenia (clinicaltrials.gov) - Oct 10, 2012
P3, N=48, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Cognitive Behavioral Therapy for Paranoia in Schizophrenia (clinicaltrials.gov) - Oct 9, 2012
P=N/A, N=24, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Enrollment closed: Factors Association With Poor Physical Function in Older Adults With Schizophrenia (clinicaltrials.gov) - Oct 7, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- AMG 579 / Amgen
Trial termination: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Oct 4, 2012
P1, N=50, Terminated, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Terminated; Amgen decision (business)
- AMG 579 / Amgen
Enrollment change: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Oct 4, 2012
P1, N=50, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Amgen decision (business) N=66 --> 50
- Clinical: PERDOVE: Outcomes and Discharge of Long-stay Psychiatric Patients (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=403, Completed, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
- | New P2 trial: Oxytocin as Adjunctive Therapy for Schizophrenia (clinicaltrials.gov) - Oct 2, 2012
P2, N=80, Recruiting, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Clinical: Switching From Consta® to Sustenna® in Patients With Schizophrenia (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=50, Recruiting, Sponsor: Seoul National University Hospital
- | pomaglumetad methionil (DB103) / Denovo
Trial termination: A Long-Term Study in Schizophrenia (clinicaltrials.gov) - Sep 27, 2012
P3, N=282, Terminated, Sponsor: Eli Lilly and Company
N=66 --> 50 Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
- | pomaglumetad methionil (DB103) / Denovo
Trial termination: A Long-Term, Open-Label, Study on Schizophrenia (clinicaltrials.gov) - Sep 27, 2012
P2/3, N=1210, Terminated, Sponsor: Eli Lilly and Company
Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
- ||| pomaglumetad methionil (DB103) / Denovo
Trial completion: A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia (clinicaltrials.gov) - Sep 27, 2012
P1, N=60, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Terminated; The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. Recruiting --> Completed
- Enrollment change: Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=120, Completed, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Completed N=100 --> 120
- Trial completion: Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=120, Completed, Sponsor: University of Medicine and Dentistry New Jersey
N=100 --> 120 Recruiting --> Completed
- Trial completion: Electronic Decision Support Systems for Smokers With Severe Mental Illness (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=142, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS) (clinicaltrials.gov) - Sep 21, 2012
P=N/A, N=60, Recruiting, Sponsor: Chiang Mai University
Recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment open: Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia (clinicaltrials.gov) - Sep 21, 2012
P=N/A, N=80, Recruiting, Sponsor: Chiang Mai University
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
- ibuprofen / Generic mfg.
Trial withdrawal: Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=0, Withdrawn, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Trial termination: Imaging Cannabinoid CB1 Receptors in Schizophrenia (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=1, Terminated, Sponsor: National Institute of Mental Health (NIMH)
Not yet recruiting --> Withdrawn Recruiting --> Terminated
- Enrollment change: Imaging Cannabinoid CB1 Receptors in Schizophrenia (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=1, Terminated, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Terminated N=60 --> 1
- ibuprofen / Generic mfg.
Enrollment change: Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=0, Withdrawn, Sponsor: Norwegian University of Science and Technology
N=60 --> 1 N=30 --> 0
- Clinical: Life Quality and Health in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=1350, Enrolling by invitation, Sponsor: University of Aarhus
- ||||| Ingrezza (valbenazine) / Neurocrine, Mitsubishi Tanabe
New P2 trial: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) (clinicaltrials.gov) - Sep 17, 2012
P2, N=109, Completed, Sponsor: Neurocrine Biosciences
- perphenazine / Generic mfg., olanzapine / Generic mfg.
Trial termination: Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=8, Terminated, Sponsor: VA Nebraska Western Iowa Health Care System
N=30 --> 0 Recruiting --> Terminated; Low enrollment rate.
- perphenazine / Generic mfg., olanzapine / Generic mfg.
Enrollment change: Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=8, Terminated, Sponsor: VA Nebraska Western Iowa Health Care System
Recruiting --> Terminated; Low enrollment rate. N=100 --> 8
- | Risperdal Consta (risperidone depot formulation) / J&J
Trial completion: The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=30, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=100 --> 8 Active, not recruiting --> Completed
- Trial completion: A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=68, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Serlect (sertindole) / Lundbeck, Abbott
Trial termination: The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=14, Terminated, Sponsor: University of Zurich
Recruiting --> Completed Active, not recruiting --> Terminated; Not enough subjects have been recruited in the expected period.
- || Enrollment change: IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=751725, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Terminated; Not enough subjects have been recruited in the expected period. N=16882267 --> 751725
- Serlect (sertindole) / Lundbeck, Abbott
Enrollment change: The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=14, Terminated, Sponsor: University of Zurich
N=16882267 --> 751725 N=60 --> 14
- | ABT 354 / AbbVie
Trial completion: A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia (clinicaltrials.gov) - Sep 13, 2012
P1, N=18, Completed, Sponsor: Abbott
N=60 --> 14 Recruiting --> Completed
- ||| Trial completion: IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=751725, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Completed
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics (clinicaltrials.gov) - Sep 12, 2012
P4, N=617, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- | Trial completion: 02VNS2009: Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia (clinicaltrials.gov) - Sep 10, 2012
P2, N=20, Completed, Sponsor: cerbomed GmbH
Recruiting --> Completed Active, not recruiting --> Completed
- || Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P3 trial: Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia (clinicaltrials.gov) - Sep 9, 2012
P3, N=74, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial, Adherence: A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate (clinicaltrials.gov) - Sep 6, 2012
P4, N=154, Completed, Sponsor: Janssen Korea, Ltd., Korea
- carbidopa/levodopa / Generic mfg.
Enrollment open: Antipsychotic Augmentation With L-Dopa (clinicaltrials.gov) - Sep 5, 2012
P2, N=24, Recruiting, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment closed: ACLAIMS: A Comparison of Long-acting Injectable Medications for Schizophrenia (clinicaltrials.gov) - Sep 5, 2012
P4, N=360, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| quetiapine / Generic mfg.
Enrollment change: ANCHOR 150: Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (clinicaltrials.gov) - Sep 4, 2012
P3, N=381, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting N=100 --> 381
- Enrollment open: Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder (clinicaltrials.gov) - Sep 3, 2012
P=N/A, N=78, Recruiting, Sponsor: University Hospital of North Norway
N=100 --> 381 Not yet recruiting --> Recruiting
- | Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy (clinicaltrials.gov) - Aug 30, 2012
P2a, N=45, Enrolling by invitation, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.